NewAmsterdam Pharma Company N.V. (NAMS) — Stock Score Summary

NewAmsterdam Pharma Company N.V. (NAMS) has a MoatMap StockRank of 32/100 based on Quality (39/100), Value (35/100), and Momentum (46/100) factor scores. The current signal is SELL. NewAmsterdam Pharma is a clinical-stage biopharmaceutical company. It lacks the validated manufacturing assets or CDMO pricing power that would align it with our healthcare themes, making it too speculative for our concentrated book.

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for cholesterol management and cardiovascular disease. Its lead program, obicetrapib, targets CETP inhibition, offering a potentially differentiated mechanism of action with broad applicability. The company's innovative approach aims to address significant unmet needs in dyslipidemia, providing a strong growth opportunity in the pharmaceutical landscape.

Key Financial Metrics

Price$30.38
Market Cap$4.1B
P/E (Forward)-25.36
Price/Book5.47
Return on Equity-29.5%
Return on Invested Capital-33.0%
Debt/Equity0.00
Gross Margin100.0%
Operating Margin-1921.7%
Revenue Growth2.1%
Free Cash Flow$-59M

NewAmsterdam Pharma Company N.V. operates in the Biotechnology industry, part of the Healthcare sector (Netherlands).

Frequently Asked Questions

What is NewAmsterdam Pharma Company N.V.’s (NAMS) StockRank?
MoatMap’s StockRank for NewAmsterdam Pharma Company N.V. (NAMS) is 32/100, with a Sell signal. It is a composite of Quality (39), Value (35), and Momentum (46) factor ranks across MoatMap’s 19,000+ stock universe.
Does NewAmsterdam Pharma Company N.V. have an economic moat?
NewAmsterdam Pharma Company N.V. (NAMS) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is NewAmsterdam Pharma Company N.V. a buy, hold, or sell?
MoatMap’s current signal for NewAmsterdam Pharma Company N.V. (NAMS) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is NewAmsterdam Pharma Company N.V. in?
NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically the Biotechnology industry (Netherlands).
Browse all ranked stocksNAMS deep dive reportAI ChampionsHow we score stocksSense-check another stock